Eli Lilly has announced a massive investment plan to establish a localized production and supply system in China, specifically targeting oral dosage forms to prepare for the surging demand in the obesity treatment market.
Strengthening local manufacturing capacity The 3 billion USD investment will focus on building an “oral solid dosage” production infrastructure at Lilly’s existing facility in Suzhou while developing a network of local partners to bolster distribution. Notably, the company has inked a 200 million USD deal with contract manufacturer Pharmaron, providing the flexibility to scale up production as needed.
Strategic focus: Oral obesity medication A key driver of this expansion is the upcoming launch of orforglipron, Lilly’s first oral obesity pill. With China’s obesity rate estimated at nearly 9% among a population of over 1 billion, the country represents a massive commercial opportunity. Orforglipron is currently under regulatory review by China’s National Medical Products Administration (NMPA).
Geopolitical and economic context This move aligns with a broader trend of Western pharmaceutical giants—including AstraZeneca, Roche, and Novartis—deepening their roots in China’s life sciences ecosystem to leverage local talent and market scale. Despite pressure from Washington to “reshore” manufacturing to the U.S., Eli Lilly is pursuing a dual-track strategy: committing tens of billions to U.S. domestic production while simultaneously integrating across the entire value chain in China, from R&D to commercialization.